PLUR (Pluri) Utang jangka cendhak marang modal

Logo korporat perusahaan Pluristem Therapeutics (PLUR)

Pluri Inc. (PLUR) specializes in the industrial creation of cellular structures using 3D technologies for medicine and nutrition. The price history on GURU.Markets shows the indicator 0.00. The business relies on ESG principles when operating bioreactors and adheres to strict bioethics. To reduce costs, Pluri Inc. (PLUR) delegates the final stages of drug testing to external partners while maintaining its leadership in cultivation.

Rasio tanggungan utang jangka cendhak marang modal: pluri-biotech.com (PLUR) kanggo 28.04.2023 - 30.10.2026
Produk merek pluri-biotech.com

A comparative asset analysis requires a liquidity assessment via the ratio of liabilities under one year to equity, where the value of 0.00 determines the level of financial pressure on the business. For Pluri Inc. (PLUR), this proportion of short-term debt to equity is critical, as the costs of scaling cell lines and clinical therapy trials directly impact default risk or resource efficiency.

Pesaing Pluri Inc.

Utang jangka cendhak marang modal ASND|MDGL (Madrigal Corp) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal CORT (Corcept Therapeutics)|Utang jangka cendhak marang modal rhythmtx.com RYTM|AKRO - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Utang jangka cendhak marang ekuitas|Rasio utang jangka cendhak marang ekuitas Crinetics Corp|NAMS (NewAmsterdam Pharma) - Utang jangka cendhak marang modal|Utang jangka cendhak marang modal soleno.life|Rasio utang jangka cendhak marang ekuitas FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Agios Pharmaceuticals Inc AGIO|GPCR - Rasio utang jangka cendhak marang ekuitas|MiMedx Group, Inc. - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal rezolutebio.com|LXRX (Lexicon Pharmaceuticals, Inc.) - Rasio utang jangka cendhak marang ekuitas|MBX: Rasio silihan jangka cendhak marang modal|ALT (Altimmune Corp) - Utang jangka cendhak marang modal|Utang jangka cendhak marang modal Aardvark Pharma|Utang jangka cendhak marang modal SGMT|Utang jangka cendhak marang ekuitas BIOA (bioagelabs.com)|Utang jangka cendhak marang ekuitas Biomea Fusion BMEA|Quince Therapeutics Inc (QNCX) - Kewajiban jangka cendhak marang modal|GUTS - Utang jangka cendhak marang ekuitas|VTVT: Utang jangka cendhak marang ekuitas|ATPC: Utang jangka cendhak marang modal|SYBX - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Spruce Biosciences (SPRB)|Rasio utang jangka cendhak marang ekuitas Galecto Corporation GLTO|Utang jangka cendhak marang ekuitas Carmell Corporation CTCX|LUMO (lumos-pharma.com) - Kewajiban jangka cendhak marang ekuitas|ONVO - Utang jangka cendhak marang ekuitas|RDUS: Utang jangka cendhak marang ekuitas